[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR0009083A - Derivado de amida, processo para a preparação de um derivado de amida, composição farmacêutica, uso de um derivado de amida, método de tratamento de doenças ou de condições médicas mediadas por citocinas - Google Patents

Derivado de amida, processo para a preparação de um derivado de amida, composição farmacêutica, uso de um derivado de amida, método de tratamento de doenças ou de condições médicas mediadas por citocinas

Info

Publication number
BR0009083A
BR0009083A BR0009083-2A BR0009083A BR0009083A BR 0009083 A BR0009083 A BR 0009083A BR 0009083 A BR0009083 A BR 0009083A BR 0009083 A BR0009083 A BR 0009083A
Authority
BR
Brazil
Prior art keywords
amide derivative
medical conditions
aryl
amino
pharmaceutical composition
Prior art date
Application number
BR0009083-2A
Other languages
English (en)
Other versions
BR0009083B1 (pt
Inventor
Dearg Sutherland Brown
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9906279.6A external-priority patent/GB9906279D0/en
Priority claimed from GBGB9926667.8A external-priority patent/GB9926667D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR0009083A publication Critical patent/BR0009083A/pt
Publication of BR0009083B1 publication Critical patent/BR0009083B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"DERIVADO DE AMIDA, PROCESSO PARA A PREPARAçãO DE UM DERIVADO DE AMIDA, COMPOSIçãO FARMACêUTICA, USO DE UM DERIVADO DE AMIDA, MéTODO DE TRATAMENTO DE DOENçAS OU DE CONDIçõES MéDICAS MEDIADAS POR CITOCINAS". A invenção refere-se aos derivados de amida de fórmula (Ia) na qual X é -NHCO- ou -CONH-; m é 0-3; R^ 1^ um grupo tal como hidróxi, halogênio, trifluoro-metila, ciano, mercapto, nitro, amino, carboxila e carbamoila; n é 0-2; R^ 2^ é um grupo tal como hidróxi, halogênio, trifluorometila, ciano, mercapto, nitro, amino e carboxila; W é hidrogênio, halogênio, (1-6C)alquila ou (1-6C)alcoxila; q é 0-4; e Q é um grupo tal como arila, ariloxila, aril-(1-6C)alcoxila, aril-amino e N-(1-6C)alquil-aril-amino; ou seus sais farmaceuticamente aceitáveis ou seus ésteres cliváveis in vivo; aos processos para sua preparação, às composições contendo-os e ao seu uso no tratamento de doenças ou de condições médicas mediadas por citocinas.
BRPI0009083-2A 1999-03-17 2000-03-13 derivado de amida compreendendo um núcleo de quinazolinona, processo para a preparação de um derivado de amida, composição farmacêutica, e, uso de um derivado de amida. BR0009083B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9906279.6A GB9906279D0 (en) 1999-03-17 1999-03-17 Amide derivatives
GBGB9926667.8A GB9926667D0 (en) 1999-11-11 1999-11-11 Amide derivatives
PCT/GB2000/000912 WO2000055153A1 (en) 1999-03-17 2000-03-13 Amide derivatives

Publications (2)

Publication Number Publication Date
BR0009083A true BR0009083A (pt) 2002-01-02
BR0009083B1 BR0009083B1 (pt) 2011-11-01

Family

ID=26315301

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0009083-2A BR0009083B1 (pt) 1999-03-17 2000-03-13 derivado de amida compreendendo um núcleo de quinazolinona, processo para a preparação de um derivado de amida, composição farmacêutica, e, uso de um derivado de amida.

Country Status (28)

Country Link
US (3) US7008945B1 (pt)
EP (1) EP1163237B1 (pt)
JP (1) JP4619545B2 (pt)
KR (1) KR100757282B1 (pt)
CN (1) CN1178932C (pt)
AR (1) AR028988A1 (pt)
AT (1) ATE266023T1 (pt)
AU (1) AU761453B2 (pt)
BR (1) BR0009083B1 (pt)
CA (1) CA2368097C (pt)
CZ (1) CZ300293B6 (pt)
DE (1) DE60010448T2 (pt)
DK (1) DK1163237T3 (pt)
ES (1) ES2219319T3 (pt)
HK (1) HK1041885A1 (pt)
HU (1) HUP0105114A3 (pt)
IL (2) IL145357A0 (pt)
MX (1) MXPA01009307A (pt)
MY (1) MY128501A (pt)
NO (1) NO323191B1 (pt)
NZ (1) NZ514195A (pt)
PL (1) PL200804B1 (pt)
PT (1) PT1163237E (pt)
RU (1) RU2260007C2 (pt)
SK (1) SK287238B6 (pt)
TR (1) TR200103336T2 (pt)
TW (1) TWI247745B (pt)
WO (1) WO2000055153A1 (pt)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772432B2 (en) 1991-09-19 2010-08-10 Astrazeneca Ab Amidobenzamide derivatives which are useful as cytokine inhibitors
GB9816837D0 (en) 1998-08-04 1998-09-30 Zeneca Ltd Amide derivatives
KR20010024175A (ko) 1997-09-23 2001-03-26 돈 리사 로얄 시토킨에 의해 매개되는 질환 치료용 아미드 유도체
ES2230853T3 (es) 1998-05-15 2005-05-01 Astrazeneca Ab Derivados de benzamida para el tratamiento de enfermedades mediadas por citoquinas.
CA2328927C (en) 1998-05-15 2008-02-19 Astrazeneca Ab Benzamide derivatives for the treatment of diseases mediated by cytokines
EP1102750A1 (en) 1998-08-04 2001-05-30 AstraZeneca AB Amide derivatives useful as inhibitors of the production of cytokines
ATE254105T1 (de) 1998-09-25 2003-11-15 Astrazeneca Ab Benzamid-derivate und ihre verwendung als cytokine inhibitoren
ATE303357T1 (de) 1999-03-17 2005-09-15 Amid-derivate
CZ300293B6 (cs) * 1999-03-17 2009-04-15 Astrazeneca Ab Nové amidové deriváty, zpusob jejich prípravy a farmaceutická kompozice, která je obsahuje
GB9906566D0 (en) 1999-03-23 1999-05-19 Zeneca Ltd Chemical compounds
GB9924092D0 (en) 1999-10-13 1999-12-15 Zeneca Ltd Pyrimidine derivatives
DE10155075A1 (de) * 2001-11-09 2003-05-22 Merck Patent Gmbh Cyclische Sulfonamide
CA2492033A1 (en) 2002-07-09 2004-01-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
PL377847A1 (pl) 2003-01-14 2006-02-20 Arena Pharmaceuticals Inc. 1,2,3-Tripodstawione pochodne arylowe i heteroarylowe jako modulatory metabolizmu oraz profilaktyka i leczenie związanych z nim zaburzeń takich jak cukrzyca i hiperglikemia
GB0324790D0 (en) * 2003-10-24 2003-11-26 Astrazeneca Ab Amide derivatives
AU2005254771A1 (en) * 2004-06-15 2005-12-29 Astrazeneca Ab Substituted quinazolones as anti-cancer agents
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
MY140868A (en) * 2004-12-24 2010-01-29 Astrazeneca Ab Amide derivatives
GB0504019D0 (en) * 2005-02-26 2005-04-06 Astrazeneca Ab Amide derivatives
BRPI0611863B1 (pt) * 2005-06-22 2021-11-23 Plexxikon, Inc Composto, bem como composição e kit compreendendo o mesmo, composto intermediário na preparação do mesmo, método para tratamento e uso do mesmo
GB0516570D0 (en) * 2005-08-12 2005-09-21 Astrazeneca Ab Amide derivatives
JP2009541310A (ja) * 2006-06-19 2009-11-26 アストラゼネカ・アクチエボラーグ イソキノリン誘導体およびサイトカイン仲介疾患の阻害剤としてのそれらの使用
US7834023B2 (en) * 2006-09-20 2010-11-16 Portola Pharmaceuticals, Inc. Substituted dihydroquinazolines as platelet ADP receptor inhibitors
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
TW200845988A (en) 2007-04-05 2008-12-01 Astrazeneca Ab New compounds and their uses 707
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
CA2695004C (en) 2007-07-17 2016-01-19 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
US7868001B2 (en) * 2007-11-02 2011-01-11 Hutchison Medipharma Enterprises Limited Cytokine inhibitors
AR073711A1 (es) 2008-10-01 2010-11-24 Astrazeneca Ab Derivados de isoquinolina
KR101739994B1 (ko) 2009-04-03 2017-05-25 에프. 호프만-라 로슈 아게 프로판-１-술폰산 ｛３-［５-（４-클로로-페닐）-１Ｈ-피롤로［２，３-ｂ］피리딘-３-카르보닐］-２，４-디플루오로-페닐｝-아미드 조성물 및 그의 용도
MA33975B1 (fr) 2009-11-06 2013-02-01 Plexxikon Inc Composés et méthodes de modulation des kinases et leurs indications d'emploi
BR112013008100A2 (pt) 2010-09-22 2016-08-09 Arena Pharm Inc "moduladores do receptor de gpr19 e o tratamento de distúrbios relacionados a eles."
LT2672967T (lt) 2011-02-07 2018-12-10 Plexxikon Inc. Junginiai ir būdai skirti kinazės moduliavimui, ir jų indikacijos
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
US9181226B2 (en) * 2011-07-18 2015-11-10 Merck Patent Gmbh Benzamides
DE102012101680A1 (de) * 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
GB201317609D0 (en) 2013-10-04 2013-11-20 Cancer Rec Tech Ltd Inhibitor compounds
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
KR102595163B1 (ko) 2015-01-06 2023-10-30 아레나 파마슈티칼스, 인크. S1p1 수용체와 관련된 상태의 치료 방법
GB201505658D0 (en) 2015-04-01 2015-05-13 Cancer Rec Tech Ltd Inhibitor compounds
KR20230160955A (ko) 2015-06-22 2023-11-24 아레나 파마슈티칼스, 인크. Ｓ1ｐ1 수용체-관련 장애에서의 사용을 위한 (ｒ)-2-(7-(4-시클로펜틸-3-(트리플루오로메틸)벤질옥시)-1,2,3,4-테트라히드로시클로-펜타[ｂ]인돌-3-일)아세트산 (화합물 1)의 결정성 ｌ-아르기닌 염
WO2017003723A1 (en) 2015-07-01 2017-01-05 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
JP6898919B2 (ja) 2015-09-23 2021-07-07 ヤンセン ファーマシューティカ エヌ．ベー． 新規化合物
US11542247B2 (en) 2015-09-23 2023-01-03 Janssen Pharmaceutica Nv Bi-heteroaryl substitute 1,4-benzodiazepines and uses thereof for the treatment of cancer
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
GB201617103D0 (en) 2016-10-07 2016-11-23 Cancer Research Technology Limited Compound
KR20190116416A (ko) 2017-02-16 2019-10-14 아레나 파마슈티칼스, 인크. 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법
WO2019023278A1 (en) 2017-07-25 2019-01-31 Crinetics Pharmaceuticals, Inc. MODULATORS OF SOMATOSTATIN AND USES THEREOF
WO2019063708A1 (en) 2017-09-29 2019-04-04 Bayer Aktiengesellschaft SUBSTITUTED 3-PHENYLQUINAZOLIN-4 (3H) -ONES AND USES THEREOF
AR112840A1 (es) 2017-09-29 2019-12-18 Bayer Ag 3- fenilquinazolin-4(3h)-onas sustituidas y sus usos
EP3873903B1 (en) 2018-10-31 2024-01-24 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
TWI721624B (zh) 2018-10-31 2021-03-11 美商基利科學股份有限公司 經取代之6-氮雜苯并咪唑化合物
WO2020237025A1 (en) 2019-05-23 2020-11-26 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
MX2022012678A (es) * 2020-04-08 2023-01-11 Remix Therapeutics Inc Compuestos y metodos para modular el corte y empalme.

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1903899A (en) 1933-04-18 Cabboxylic acid abylides oe the benzene sebies and process oe making
DE522788C (de) 1928-11-01 1931-04-15 I G Farbenindustrie Akt Ges Verfahren zur Darstellung von Carbonsaeurearyliden der Benzolreihe
US1909960A (en) 1929-08-06 1933-05-23 Du Pont Intermediate for azo dyes
BE611898A (pt) 1960-12-23
US3755332A (en) 1971-07-01 1973-08-28 Ciba Geigy Corp Substituted 4 indazolaminoquinolines
DE2812252A1 (de) 1978-03-21 1979-10-04 Bayer Ag 1,2,4-triazol-blockierte polyisocyanate als vernetzer fuer lackbindemittel
US4367328A (en) 1981-03-05 1983-01-04 The Dow Chemical Company Epoxy resins from hydroxy benzamides
US4524168A (en) 1981-11-18 1985-06-18 Ciba-Geigy Corporation Process for the mass coloration of polymers
US4749729A (en) 1984-06-21 1988-06-07 American Cyanamid Company Epoxy resin compositions curable above 160 F. and below 250 F.
JPS61204221A (ja) 1985-03-07 1986-09-10 Hitachi Chem Co Ltd 熱硬化性樹脂組成物
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
AU2552492A (en) 1991-08-23 1993-03-16 United States of America as represented by The Secretary Department of Health and Human Services, The Raf protein kinase therapeutics
GB9816837D0 (en) 1998-08-04 1998-09-30 Zeneca Ltd Amide derivatives
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
GB9314884D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Tricyclic derivatives
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US5550132A (en) 1994-06-22 1996-08-27 University Of North Carolina Hydroxyalkylammonium-pyrimidines or purines and nucleoside derivatives, useful as inhibitors of inflammatory cytokines
EP0871444A4 (en) 1995-08-10 1999-01-13 Merck & Co Inc 2.5 SUBSTITUTED ARYL PYRROL, THE COMPOSITIONS THAT CONTAIN AND THE USE THEREOF
WO1997008133A1 (en) 1995-08-22 1997-03-06 Japan Tobacco Inc. Amide compounds and use of the same
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
GB9604926D0 (en) 1996-03-08 1996-05-08 Sandoz Ltd Organic compounds
EP0888335A4 (en) 1996-03-13 2002-01-02 Smithkline Beecham Corp NEW PYRIMIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CYTOKININ MEDIATOR DISEASES
EP0922042A1 (en) 1996-08-09 1999-06-16 Smithkline Beecham Corporation Novel piperazine containing compounds
GB9623833D0 (en) 1996-11-16 1997-01-08 Zeneca Ltd Chemical compound
US6103737A (en) 1997-07-03 2000-08-15 Dupont Pharmaceuticals Company Aryl- and arylamino- substituted heterocycles as corticotropin releasing hormone antagonists
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
KR20010024175A (ko) 1997-09-23 2001-03-26 돈 리사 로얄 시토킨에 의해 매개되는 질환 치료용 아미드 유도체
UA72458C2 (uk) 1998-03-27 2005-03-15 Янссен Фармацевтика Н.В. Похідні піримідину, спосіб їх отримання, фармацевтична композиція на їх основі, спосіб її отримання, комбінація сполук та продукт для лікування віл
ES2230853T3 (es) 1998-05-15 2005-05-01 Astrazeneca Ab Derivados de benzamida para el tratamiento de enfermedades mediadas por citoquinas.
CA2328927C (en) * 1998-05-15 2008-02-19 Astrazeneca Ab Benzamide derivatives for the treatment of diseases mediated by cytokines
EP1102750A1 (en) * 1998-08-04 2001-05-30 AstraZeneca AB Amide derivatives useful as inhibitors of the production of cytokines
EP1110951B1 (en) 1998-08-27 2004-05-19 Sumitomo Pharmaceuticals Company, Limited Pyrimidine derivatives
DE69933680T2 (de) 1998-08-29 2007-08-23 Astrazeneca Ab Pyrimidine verbindungen
DE69932828T2 (de) 1998-08-29 2007-10-18 Astrazeneca Ab Pyrimidine verbindungen
ATE254105T1 (de) 1998-09-25 2003-11-15 Astrazeneca Ab Benzamid-derivate und ihre verwendung als cytokine inhibitoren
NZ510210A (en) 1998-10-01 2003-06-30 Astrazeneca Ab 4-phenylamino substituted quinazoline or quinoline derivatives useful for treating cytokine mediated diseases or conditions
ATE303357T1 (de) 1999-03-17 2005-09-15 Amid-derivate
CZ300293B6 (cs) 1999-03-17 2009-04-15 Astrazeneca Ab Nové amidové deriváty, zpusob jejich prípravy a farmaceutická kompozice, která je obsahuje
GB9906566D0 (en) * 1999-03-23 1999-05-19 Zeneca Ltd Chemical compounds
GB9924092D0 (en) 1999-10-13 1999-12-15 Zeneca Ltd Pyrimidine derivatives
EA007538B1 (ru) 2000-12-11 2006-10-27 Туларик Инк. Антагонисты cxcr3
TW200306839A (en) 2002-02-06 2003-12-01 Novartis Ag Quinazolinone derivatives and their use as CB agonists
GB0324790D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Amide derivatives

Also Published As

Publication number Publication date
NO20014492D0 (no) 2001-09-14
HUP0105114A2 (hu) 2002-07-29
HUP0105114A3 (en) 2002-09-30
HK1041885A1 (en) 2002-07-26
US7442704B2 (en) 2008-10-28
RU2260007C2 (ru) 2005-09-10
NO323191B1 (no) 2007-01-15
PT1163237E (pt) 2004-08-31
US7332483B2 (en) 2008-02-19
NZ514195A (en) 2004-05-28
DE60010448T2 (de) 2005-04-07
CZ300293B6 (cs) 2009-04-15
IL145357A0 (en) 2002-06-30
AU761453B2 (en) 2003-06-05
ES2219319T3 (es) 2004-12-01
ATE266023T1 (de) 2004-05-15
US7008945B1 (en) 2006-03-07
US20060281734A1 (en) 2006-12-14
CN1350530A (zh) 2002-05-22
AR028988A1 (es) 2003-06-04
MXPA01009307A (es) 2002-07-30
TR200103336T2 (tr) 2002-04-22
WO2000055153A1 (en) 2000-09-21
CA2368097A1 (en) 2000-09-21
BR0009083B1 (pt) 2011-11-01
JP4619545B2 (ja) 2011-01-26
IL145357A (en) 2007-07-24
CA2368097C (en) 2010-01-19
EP1163237B1 (en) 2004-05-06
NO20014492L (no) 2001-11-12
SK287238B6 (sk) 2010-04-07
PL200804B1 (pl) 2009-02-27
US20050245551A1 (en) 2005-11-03
SK13112001A3 (sk) 2002-06-04
PL350451A1 (en) 2002-12-16
TWI247745B (en) 2006-01-21
EP1163237A1 (en) 2001-12-19
MY128501A (en) 2007-02-28
CN1178932C (zh) 2004-12-08
JP2002539207A (ja) 2002-11-19
DK1163237T3 (da) 2004-08-02
CZ20013319A3 (cs) 2001-12-12
KR20010113756A (ko) 2001-12-28
KR100757282B1 (ko) 2007-09-11
AU3177800A (en) 2000-10-04
DE60010448D1 (de) 2004-06-09

Similar Documents

Publication Publication Date Title
BR0009083A (pt) Derivado de amida, processo para a preparação de um derivado de amida, composição farmacêutica, uso de um derivado de amida, método de tratamento de doenças ou de condições médicas mediadas por citocinas
BR0009041A (pt) Derivado de amida, processo para a preparação deum derivado de amida, composição farmacêutica,uso de um derivado de amida, e, método paratratar doenças ou quadros clìnicos mediados porcitocinas
BR9913947A (pt) Derivado de amida, processo para a preparação do mesmo ou um sal farmaceuticamente aceitável ou éster clivável in vivo deste, uso do mesmo, e, composição farmacêutica
BR0014596A (pt) Derivado de pirimidina, uso do mesmo, composição farmacêutica, e, método de tratar doenças ou condições médicas mediadas por citocinas
BR0308875A (pt) Composto ou um sal farmaceuticamente aceitável ou amida ou éster deste hidrolisável in vivo, processo para prepará-lo, composição farmacêutica, uso do composto da fórmula de um sal farmaceuticamente aceitável ou amida ou éster deste hidrolisável in vivo, e, métodos para produzir um efeito inibidor de hdac e para tratar o câncer em um animal de sangue quente, tal como o homem, em necessidade de tal tratamento
BR9914162A (pt) Derivado de amida, processo para preparar um derivado de amida, ou um sal farmaceuticamente aceitável ou éster clivável in vivo do mesmo, composição farmacêutica e uso de um derivado de amida, ou um sal farmaceuticamente aceitável ou éster clivável in vivo do mesmo
BR9910467A (pt) Composto derivado de amida, processo para a preparação do mesmo, composição farmacêutica, e, uso de um composto derivado de amida
BR0206435A (pt) Composto, composição farmacêutica, métodos de tratar a angiogênese em um paciente, de tratar distúrbios relacionados com kdr e proliferativos em um mamìfero, uso de um composto, e, processo para preparar compostos
IL127296A0 (en) Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
BR9912729A (pt) Derivado de amida, processo para prepará-lo, e, uso do mesmo
WO2001064639A3 (en) Pde iv inhibiting amides, compositions and pharmaceutical use
BR0309553A (pt) Composto ou sal farmaceuticamente aceitável ou éster ou amida hidrolisável in vivo deste, processo para prepará-lo, composição farmacêutica, uso do composto, e, métodos para produzir um efeito inibidor de hdac em um animal de sangue quente, e para tratar câncer em um animal de sangue quente
AP2000001860A0 (en) Hypolipidemic benzothiazepine compounds.
HUP0400710A2 (hu) Tioéter helyettesítővel helyettesített imidazokinolinszármazékok, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
UA66852C2 (uk) Похідні та аналоги 3-арилпропіонової кислоти, спосіб їх отримання, фармацевтична композиція (варіанти) та спосіб профілактики та/або лікування асоційованих з резистентністю до інсуліну клінічних станів
BR0308145A (pt) Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
BR0012157A (pt) Derivado de quinazolina, derivado de pirimidina, processo para a preparação de um derivado de quinazolina, composição farmacêutica, uso de um derivado de quinazolina, e, método para a prevenção ou tratamento de doenças ou condições médicas pela célula t um em animal de sangue quente em necessidade de tal tratamento
HUP0100865A2 (hu) Meta-azaciklusos csoporttal N-szubsztituált amino-benzoesav-vegyületek és származékaik mint integrin antagonista hatóanyagok, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk
HUT65351A (en) Process for preparing ethanolamine derivatives haring sympathominetic and anti-pollakiuria activity and pharmaceutical compositions containing them as active agent
NO20040589L (no) Arylsulfonylderivater med 5-HT6 reseptor affinitet.
IL126825A (en) beta-Alanine drivatives processes for their preparation and pharmaceutical compositions containing them
ATE201671T1 (de) Chinolon und acridinon derivate zur behandlung der harninkontinenz
BR0315958A (pt) Composto, composição farmacêutica, processo para a preparação de um composto, novos intermediários e uso do composto
HUP0003577A2 (hu) Tetrahidro-gamma-karbolinok, eljárás előállításukra, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
HUP0401588A2 (hu) Rákellenes és proliferáció elleni hatású indeno[1,2-c]pirazol-4-on-származékok és ezeket tartalmazó gyógyszerkészítmények

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 01/11/2011, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 14A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2259 DE 22-04-2014 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.